RPAM
VIR icon

Rhenman & Partners Asset Management’s Vir Biotechnology VIR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$1.3M – 104
2025
Q1 		$1.3M Buy
+200,000
New +$1.78M 0.15% 76

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rhenman & Partners Asset Management's VIR Position: Q2 2025 in Review

Rhenman & Partners Asset Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 200,000 shares — an estimated $1.3M sold.

Rhenman & Partners Asset Management first reported a position in VIR in Q1 2025 and held it in 1 quarter. The position peaked at $1.3M in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Rhenman & Partners Asset Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 200,000 Vir Biotechnology shares in Q2 2025, an estimated $1.3M.
  • Rhenman & Partners Asset Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Vir Biotechnology position peaked at $1.3M in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.